The potential for Zika virus (ZIKV) transfusion-transmission (TT) has been demonstrated in French Polynesia and Brazil. Pathogen inactivation (PI) of blood products is a proactive strategy to inactivate TT pathogens including arboviruses. Inactivation of West Nile, dengue, Zika, and chikungunya viruses was previously demonstrated by photochemical treatment with amotosalen and ultraviolet A (UVA) illumination. In this study, we evaluated ZIKV inactivation in red blood cell (RBC) components by a chemical approach that uses amustaline (S-303) and glutathione (GSH).
The second outbreak occurred in French Polynesia (FP) from 2013 to 2014, 1, 4 resulting in approximately 32,000
infections and, for the first time, an association between ZIKV and severe disease outcomes was established, including a 20-fold increase in instances of Guillain-Barr e syndrome. 5 Additionally, the potential for non-vectorborne ZIKV transmission via blood transfusion and maternofetal or sexual transmission was first demonstrated during this outbreak. [6] [7] [8] From FP, ZIKV spread in the Pacific 9 and emerged in the Americas in 2015, 10 where it was associated with a dramatic increase in incidence of central nervous system fetal or neonatal abnormalities, including microcephaly. 11, 12 This led the World Health Organization (WHO) to declare a global health emergency in February 2016. 13 ZIKV has now spread throughout nearly all of Latin America and the Caribbean, with additional outbreaks in Africa (Cape Verde) in 2015 and Puerto Rico, the continental United States (Florida), and Asia (Singapore) in 2016. 1, [14] [15] [16] From 2007 to September 2016, a total of 72 countries and territories have reported evidence of ZIKV transmission; 20 have reported microcephaly and other central nervous system malformations potentially associated with ZIKV, while 18 have reported an increase in incidence in Guillain-Barr e syndrome. 16 An estimated 2.2 billion people are considered to live in high-risk areas for ZIKV circulation throughout the world, where the main mosquito vectors, Aedes aegypti and Aedes albopictus, are present. 17 As transfusion transmission (TT) of arboviruses, such as West Nile virus (WNV), 18 dengue virus (DENV), 19 Ross
River virus, 20 and yellow fever virus, 21 has been previously demonstrated, the potential for ZIKV TT became a concern and mitigation strategies were explored in FP. 22 While no symptomatic ZIKV TT was reported during the FP outbreak, 23 several cases of ZIKV TT were reported in Brazil in December 2015 24 and later in 2016, 25, 26 confirming ZIKV as a new challenge for the safety of the blood supply. 27, 28 However, as it is challenging to prove non-vectorborne transmission of arboviruses in endemic areas, 29 and because most endemic areas lack the capacity to detect ZIKV in blood donations, the number of TT ZIKV infections is likely underestimated. The first international recommendation to prevent ZIKV TT was issued by the European Center for Disease Prevention and Control in 2014. 30 The spread of ZIKV throughout the Caribbean and the concerns over the safety of the blood supply in Puerto Rico triggered the release of guidelines by the Food and Drug Administration (FDA), 31, 32 the WHO, 33 and the AABB 34 aimed at preventing ZIKV TT. In US areas with active ZIKV circulation, the main recommendations included donor deferral, blood collection suspension, and importation of blood components from nonactive transmission areas and either implementation of ZIKV nucleic acid testing (NAT) or pathogen inactivation (PI). PI is a proactive strategy designed to reduce or eliminate infectivity of bacteria, viruses, and parasites in blood. 35 Several processes have been developed for the inactivation of pathogens in fresh-frozen plasma and platelet (PLT) concentrates. 35 In FP, the INTERCEPT Blood System for PLTs (Cerus Corporation), a CE mark-approved technology, was implemented in 2010 and has since been used routinely. During the FP ZIKV outbreak, plasma units were imported from metropolitan France. 22 However, during the outbreak, no PI technology was commercially available for red blood cell (RBC) treatment.
The INTERCEPT Blood System for RBCs uses a chemical treatment with the small molecule amustaline (S-303) that forms covalent crosslinks and adducts with nucleic acids resulting in the inactivation of pathogens. S-303 is a reactive modular compound that is designed to react quickly and then decompose by hydrolysis to the nonreactive compound S-300 (Fig. 1) . It is formulated in the presence of the natural tripeptide glutathione (GSH) to quench unreacted side reactions. S-303 has been shown to inactivate a variety of enveloped and nonenveloped viruses, Gram-positive and -negative bacteria, parasites, 36 and white blood cells. 37 S-303 has been shown to be effective against bovine viral diarrhea virus, a member of the Flaviviridae family and a model for hepatitis C virus, but specific data for ZIKV are lacking. 36 To evaluate the S-303 and GSH systems' ability to inactivate ZIKV in RBCs, RBC components were spiked with high levels of ZIKV, and tissue culture infectivity levels and RNA loads were determined before and after S-303 and GSH treatment, in accordance with the recommendations for evaluation of PI efficacy. 38 This study is the first to demonstrate that inactivation to the limit of detection for high ZIKV titers can be achieved in RBCs.
MATERIALS and METHODS

Experimental design
Whole blood units were converted to AS- Inoculation of RBC components with ZIKV and inactivation process
Four RBC components (Units 1, 2, 3, and 4) were inoculated with ZIKV as previously described. 39 In this experiment, three of the units (Units 1, 2, and 3) were treated with S-303 and GSH, while the fourth unit (Unit 4) was "mocktreated" and received equal volumes of saline in lieu of both S-303 and GSH solutions (Fig. 2) . The INTERCEPT Blood System for RBCs includes an S-303 vial, a GSH vial, a trifurcated set with two 0.2-mm filters, and a processing set with three containers: a mixing bag containing a proprietary processing solution, an incubation bag, and a storage bag containing SAG-M (shown in Fig. 3 ).
Each ZIKV-contaminated RBC unit was sterile connected to one end of the trifurcated set while the other end of the trifurcated filter set was sterile connected to the mixing bag. GSH solution or saline was added to the mixing bag through one of the 0.2-mm filter ports, and the ZIKV-inoculated RBCs were transferred to the mixing bag and mixed. Two preinactivation untreated test (UT) samples were taken from all 4 units: one was frozen immediately after collection (UT0), and the other was allowed to incubate at room temperature for 20 hours (UT20h). After sampling, S-303 or saline was added to the RBCs, via the second 0.2-mm filter. RBCs dosed with S-303 and GSH or saline were transferred to the incubation bag and stored at room temperature for 20 hours. The incubation bag was then centrifuged to separate the RBCs, and the supernatant was expressed into the mixing bag that was then sealed off and discarded. The treated RBCs were resuspended in SAG-M and then transferred to the final storage container. Inactivated treated test (TT) samples (TT20h) were taken from the treated Units 1, 2, and 3 (which received S-303 and GSH), while noninactivated test samples were taken from the mock-treated Unit 4 (which received saline in lieu of S-303 and GSH) (Fig. 2) . All samples were frozen at 2808C until analysis.
Detection of replicative ZIKV and viral infectivity titration
For the detection of infectious ZIKV, all preinactivation, postinactivation, and noninactivated samples were inoculated in triplicate on Vero cells in 24-well plates, and five consecutive passages were performed as previously described. 39 After each passage, indirect immunofluorescence assay (IFA) was performed, as previously described, 39, 41 to detect ZIKVinfected cells, using anti-flavivirus mouse antibodies 4G2 (Institut Pasteur, Paris, France) at a dilution of 1:50 in phosphate-buffered saline (PBS, bioM erieux). For viral titration, triplicate 10-fold dilutions of all samples were inoculated on Vero cells in 96-well plates. Inoculated cells were maintained at 378C in an atmosphere of 5% CO 2 for 6 days and then were washed with PBS. Cells were fixed in cold acetone and air-dried. The presence of ZIKVinfected cells was detected by IFA using antibodies 4G2 at a dilution 1:400 in PBS. Infectious wells were enumerated for each dilution using a fluorescence microscope and viral titers were expressed as 50% tissue culture infectious dose (TCID 50 /mL) using the method of Reed and Muench. 42 
ZIKV RNA quantitation
For all RBC (preinactivation, postinactivation, and untreated) samples and cell supernatants, RNA extractions were performed from 200 mL of each sample using an extraction system (QIAcube, Qiagen), and realtime reverse transcription-polymerase chain reaction (RT-PCR) assays were performed in a thermocycler (CFX96, Bio-Rad) using primers ZIKV 835 and ZIKV 911c and probe 860-FAM, as previously described. 39 To quantify the ZIKV RNA copy number (genomic equivalents [geq]/mL), an RNA synthetic transcript was serially diluted and included within the RT-PCR run to generate a standard curve. The amplicon was prepared with an in vitro transcription system (Riboprobe System-T7, Promega), from strain PF13/251013-18 and quantified using an RNA assay kit with a fluorimeter (Quant-iT and Qubit, Invitrogen). The limit of detection for this assay is 100 geq, while the amplified region was 75 bp long. 6 
RESULTS
Detection of replicative ZIKV and ZIKV titration
For Units 1 to 3, viral titers in preinactivation samples ( Fig. 2; UT0 ) averaged 5.99 6 0.2 log TCID 50 /mL, while viral titers in the noninactivated control samples ( Fig. 2; UT20h; Units 1-3) averaged 5.27 6 0.14 log TCID 50 /mL ( Table 1 ). The titers in the mock-treated Unit 4 were comparable for the pretreatment samples at 6.72 log TCID 50 / mL (UT0) and nontreated control samples at 5.50 log TCID 50 /mL (UT20h). For Unit 4, the reduction observed for the mock posttreatment sample (reduced to 3.95 log TCID 50 /mL) is consistent with the dilution of the virus during the exchange process, if one assumes an even distribution in the total volume during the dilution and volume exchange process. The culture of preinactivation (UT0; Units 1-3), noninactivated control samples (UT20h; Units 1-3), and mock-treated control and postinactivation (UT0, UT20h, TT20h; Unit 4) samples produced replicative viruses during successive passages, as demonstrated with IFA (Table 1) . No replicative virus was detected in postinactivation samples (TT20h; Units 1-3), even after five passages on Vero cells (Table 1) .
ZIKV RNA quantitation
For Units 1-3, viral RNA loads averaged 7.75 6 0.16 log geq/mL in preinactivation samples (Units 1-3; UT0) and 7.32 6 0.14 log geq/mL in noninactivated control samples (Units 1-3; UT20h; Table 2 ). Immediately after inactivation (TT20h; Units 1-3), ZIKV RNA loads averaged 5.17 6 0.45 log geq/mL, as RNA is still present due to the presence of inactivated virus incapable of replication. The small reduction of approximately 2 log is mostly due to the dilution of the inactivated virus after exchange. Subsequent passages of the inactivated samples were performed. After the first passage of inactivated samples (TT20h; Units 1-3; 
DISCUSSION
The ZIKV crisis is a reminder that with the global emergence of arboviruses, 43, 44 primarily due to the expansion of the mosquito range and the increase of global transportation and migration, the potential for new outbreaks caused by emerging agents is increasing throughout the world. In certain parts of the world, several pathogens with the potential to be transmitted by blood transfusion may cocirculate and the numerical increase of screening assays necessary to detect them may be a logistic and financial challenge. Multiplex arbovirus NAT assays can be developed (e.g., the Trioplex CDC assays for simultaneous detection of DENV, CHIKV, and ZIKV RNA) 45 ). In addition, these pathogens frequently emerge in countries with limited resources, giving less incentive to manufacturers to develop validated NAT blood screening assays in the absence of a mandate. Given their rapid emergence and lack of predictability, emerging pathogens challenge the current testing paradigm, a reactive approach that works best for characterized pathogens. Characterization of pathogens takes time after recognition, which is particularly challenging in countries with few resources that may have to rely on insensitive rapid tests for the screening of blood products. 46, 47 An alternate way to manage the continuous threat of emerging infectious agents is the use of PI technologies to proactively protect the blood supply and mitigate the risk of TTIDs. Over the past 10 years, great strides have been made in the approval and routine use of PI technologies for plasma and PLTs in Europe (INTERCEPT, Theraflex, Mirasol) and the United States (INTERCEPT for PLTs and plasma, Octaplas for plasma). Some of these technologies have been found to be effective for the inactivation of emerging pathogens but there are significant differences between technologies.
The amotosalen/UVA system, which was approved in France in 2005, has been routinely used for PLT components in the French overseas territories and departments since its implementation in La Reunion in 2006, in Martinique and Guadeloupe in 2007, and in FP in 2010 to prevent CHIKV and DENV infections. 22, 48 Therefore, at the time of the ZIKV outbreak in FP, all PLT components were pathogen inactivated and protected based on previous experience with CHIKV (>6.4 log reduction), 49 DENV (>5.3 log reduction), 50 and WNV (>5.5 log reduction reduction).
51
The S-303 and GSH INTERCEPT Blood System for RBCs is in an advanced development stage and a clinical trial has recently been completed in Europe. 52 This technology bypasses the technical issue of light absorption by RBCs, which reduces efficacy of photochemical methods, 53 by utilizing a chemical, rather than photochemical, treatment. Thus, the treatment does not require an illumination device and is performed at room temperature with a single centrifugation step to exchange the treatment solution for SAG-M for pathogen-reduced RBC manufacturing. These properties make it feasible for remote areas where refrigerated transportation of samples and laboratory reagents to a central testing facility is a challenge. While the efficacy of the S-303 and GSH system continues to be characterized for various bacteria and viruses, including other flaviviruses, as part of the product development, our study was performed to evaluate the level of ZIKV inactivation in RBCs. The findings demonstrated that the mean inactivation of ZIKV in RBCs using this system is more than 5.99 log TCID 50 /mL and more than 7.75 log geq/mL with complete inactivation of ZIKV infectivity after treatment of RBCs. The data in this study are consistent with inactivation of infectivity to the level of detection achievable with cellular infectivity assays (i.e., less than 1 pfu/mL). In addition, treated products were passaged five times on Vero cells to amplify residual infectious viral particles. The same method was previously used to demonstrate the efficacy of the amotosalen/UVA system to inactivate DENV and ZIKV in plasma. 39, 41 Indeed, a robust level of ZIKV inactivation (>6.57 log TCID 50 /mL and >10.25 log RNA geq/mL) in plasma was reached after treatment with the amotosalen/UVA system. 41 Such experiments are usually performed using plaque assays that are limited by the infectivity achievable in a single blood unit, while the method used in this study utilizes cell culture passages to enhance the sensitivity of the assay and to correlate the reduction of infectivity with that of amplifiable geq as a function of sequential passages, demonstrating a lack of tissue infectivity despite the positive initial signal. 36, [54] [55] [56] Amotosalen/UVA and S-303 and GSH systems have the same mode of action: they react with nucleic acids and modify them to prevent their replication, transcription, and translation (Fig. 1) . However, in contrast to prior ZIKV inactivation studies using the amotosalen/UVA for plasma, in this study, neither viral RNA nor infectivity was quantifiable by RT-PCR or cell culture at the first passage after PI treatment. The observed inhibition of amplification of small amplicons by RT-PCR is unusual and may denote a more effective nucleic acid modification after S-303 and GSH treatment. 57, 58 Importantly, before S-303 and GSH treatment and subsequent complete inactivation, the genomic titers of ZIKV in the RBCs units (Units 1-3 62 as previously reported for WNV. 63 Recently, FDA and CDC called for "interventions that are both precautionary and independent of the specific threat such as PI technologies for all blood components". 64 Robust and broad-spectrum technologies may constitute the best approach in preparation for the next emerging TT infectious disease. No PI technologies are currently approved for use in RBCs and additional clinical studies are under way to further study the safety of the S-303 and GSH system for broad clinical use in patients suffering from acute or chronic anemia of all age groups. After approval of this PI technology for RBCs, the collection of routine-use data through hemovigilance may be the best way of ensuring safety and efficacy of this product. Long-term-use data may alleviate concerns about unanticipated side effects, including immunogenicity, and highlight any positive synergistic effects of PI products. Routine-use analysis may also be the best way to evaluate the pharmacoeconomics of such products and address current concerns about cost to implement. A key consideration may be the compatibility of the PI process with current component manufacturing and local practices, as well as the ability to treat all types of RBCs.
The results of this study complement previous results 65 and show that ZIKV can be inactivated in all blood components (Table 3 ) using amotosalen/UVA for PLTs and plasma 41 and S-303 and GSH for RBCs. The availability of broad spectrum PI technologies for all blood components enables a new paradigm for blood safety that can be used to maintain the ongoing availability and safety of blood products in time of epidemics with newly emerged and potentially susceptible pathogens.
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